Ozgur Sahin was recognized for his work and article, “Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer,” published by Nature Communications Nov. 2, 2023. https://medicine.musc.edu/research/excellence-awards
We are thrilled to share the news that Ozge, our PhD candidate, has successfully defended her thesis entitled “Targeted Multimodal Approaches to Treat Aggressive Breast Cancers via Therapeutic Inhibition of Key Vulnerabilities.” Her completion of the PhD program is distinguished by a noteworthy contribution of high-impact papers in the field. We have every confidence that she will continue to achieve even more in her future endeavors!
We participated in the Drug Discovery and Development Retreat organized by MUSC and USC. During the event, we had the opportunity to engage with numerous presentations on translational cancer research, including Dr. Sahin’s insightful talk on “From mechanism of resistance to drug discovery: Targeting the most aggressive breast cancers.” Members of our lab, namely Ozge, Metin, and Emre, presented their research through poster presentations. We are proud to announce that Ozge received the Best Poster Read more…
The National Cancer Institute has awarded Dr. Sahin’s startup, LoxiGen, Inc., a three-year Fast-track Small Business Technology Transfer (STTR) grant to develop therapy for drug-resistant TNBC in collaboration with scientist at MUSC and USC
Our LOXi project featured in the Cancer Letter! Here is the press release: https://cancerletter.com/drugs-and-targets/20230630_8c/
Ozge Saatci received the Scholar-in-Training award to attend the American Association for Cancer Research conference and present her research. Here is the press release: https://hollingscancercenter.musc.edu/news/archive/2023/04/24/hollings-team-ids-protein-that-helps-cancer-cells-in-cell-division-process